Zobrazeno 1 - 10
of 188
pro vyhledávání: ''
Autor:
Karen Kelly, Everett E. Vokes, Jonathan W. Goldman, Rebecca S. Heist, Apurvasena Parikh, D. Ross Camidge, J. Wu, Minal A. Barve, Bruce A. Bach, Eric Angevin, Zhaowen Sun, David S. Hong, Philip Komarnitsky, John H. Strickler, Todd M. Bauer, Daniel Morgensztern, Monica Motwani
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(21)
Purpose: Telisotuzumab vedotin (Teliso-V) is an anti–c-Met–directed antibody–drug conjugate. Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V monotherapy evaluated in once every 2 weeks/once every 3 weeks schedules
Autor:
Alexandra Thomas, Kathy D. Miller, Susan M. Perkins, Sagar Sardesai, Robert E. Stratford, Tarah J. Ballinger, Amber Bauchle, Yvonne L. Ottaviano, Sandra K. Althouse, Bryan P. Schneider, Filipa Lynce, Andrea R. Masters, Zizheng Dong, Jian-Ting Zhang, Jing-Yuan Liu, Christopher Gallagher, Anna Maria Storniolo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(21)
Purpose: Fatty acid synthase (FASN) is overexpressed in 70% of operable triple-negative breast cancer (TNBC) and is associated with poor prognosis. Proton pump inhibitors selectively inhibit FASN activity and induce apoptosis in TNBC cell lines. Pati
Autor:
Yen Y. Wang, Stephen K. Williamson, Karissa Finke, Jecinta Scott, Bruce F. Kimler, Priyanka Sharma, Andrew K. Godwin, Gregory A. Reed, Marc Hoffmann, Shane R. Stecklein, Rachel Yoder, Lauren Nye, Anne O'Dea, Qamar J. Khan, Sharon Lewis, Milind A. Phadnis, Stephanie LaFaver, Jaimie Heldstab, Jilliann A De Jong, Ingrid A. Mayer, Manana Elia, Vandana G Abramson, Harsh B. Pathak, Kelsey Schwensen
Publikováno v:
Clin Cancer Res
Purpose:PIK3CA mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients with HER2-negative metastatic breas
Autor:
Dawei Xuan, Valentina Boni, Xiaohua Xin, Shilpa Alekar, Anthony W. Tolcher, Jasgit C. Sachdev, Nehal Lakhani, Victor Moreno, Ruifeng Li, Amy Jackson-Fisher, Erica Stringer-Reasor, Michael L. Maitland, Allison R Moreau, Shivaani Kummar, Michelle Bowers, Emiliano Calvo, Eric L. Powell, Manish R. Sharma
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(16)
Purpose: We investigated safety, tolerability, pharmacokinetics, and antitumor activity of the protein tyrosine kinase 7 (PTK7)-targeted, auristatin-based antibody–drug conjugate (ADC) PF-06647020/cofetuzumab pelidotin (NCT02222922). Patients and M
Autor:
Judy S. Wang, Manuel Selvi Miralles, Daniel P. Petrylak, Peng He, John G. Bothos, Kapil Vashisht, Marna Williams, Qu Zhang, Mark D. Fleming, Mary Jane Hinrichs, Pablo Martinez, Anton I. Rosenbaum, Johann S. de Bono, Song Cho, Richard Cathomas, Meina Liang
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(13)
Purpose: MEDI3726 is an antibody–drug conjugate targeting the prostate-specific membrane antigen and carrying a pyrrolobenzodiazepine warhead. This phase I study evaluated MEDI3726 monotherapy in patients with metastatic castration-resistant prosta
Autor:
Farasat Kazmi, Shibani Nicum, David J. Harrison, Hani Gabra, Ajithkumar Sukumaran, Chat Gnanaranjan, Nigel W McCracken, Laura Spiers, Sarah P. Blagden, Essam Ghazaly, Rene L Roux
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(11)
Purpose: NUC-1031 is a first-in-class ProTide modification of gemcitabine. In PRO-002, NUC-1031 was combined with carboplatin in recurrent ovarian cancer. Patients and Methods: NUC-1031 was administered on days 1 and 8 with carboplatin on day 1 every
Autor:
Victor Moreno, Noboru Yamamoto, Zhuqing Tina Liu, Min Hee Hong, Boris Calderon, Amita Patnaik, Leena Gandhi, Jose Manuel Trigo, Danni Yu, Ching Ching Leow, Emiliano Calvo, Violeta Regnier Galvao, Nieves Velez de Mendizabal, Yung Jue Bang, Toshihiko Doi, James J. Harding, Maria de Miguel, Siqing Fu, Anna M. Szpurka
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(8)
Purpose: T-cell immunoglobulin and mucin-domain–containing molecule-3 (TIM-3) blunts anticancer immunity and mediates resistance to programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors. We assessed a novel, first-in-class, TIM-3 mAb, LY3321
Autor:
Joachim P. Steinbach, Catya Munhoz, Carol Peña, Volker Heinemann, Susanne Reschke, Cristiana Roggia, Yoshitaka Narita, Michael C. Burger, Sant P. Chawla, Katharina J. Wenger, Simon Langer, Antje Wick, Ulrik Lassen, Stefan Kaulfuss, Michael Jeffers, Kamalesh Kumar Sankhala, Christine Rentzsch, Filip Janku, Heinz-Josef Lenz, Yuichi Ando, Martin Schuler, Masafumi Ikeda, Markus Wagner, Isabelle Genvresse, Eleni Lagkadinou, Oliver Bähr, Kristoffer Staal Rohrberg, Charles Cai, Wolfgang Wick, David Schiff, Ghazaleh Tabatabai
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(10)
Purpose: BAY1436032, an inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), was active against multiple IDH1-R132X solid tumors in preclinical models. This first-in-human study was designed to determine the safety and pharmacokinetics of BAY14360
Autor:
Chia-Chi Lin, Timothy A. Yap, Anna M. Szpurka, Maria de Miguel, Xiaojian Xu, Shelly Schmidt, Kay Hoong Chow, Antoine Italiano, Yumin Zhao, Yung Jue Bang, Michelle Carlsen, Wu Chou Su, Hyun Cheol Chung, Amita Patnaik, Burkhard Vangerow, Johanna C. Bendell, Danni Yu, Leena Gandhi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(5)
Purpose: This phase Ia/Ib PACT study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of a new programmed cell death ligand 1 (PD-L1) inhibitor, LY3300054, as monotherapy or in combination with ramucirumab, abemaciclib
Autor:
Patricia Niccoli, I. Aronchik, Ruth Plummer, T. Sánchez-Pérez, Victor Moreno, E. Filvaroff, Nicolas Isambert, Patricia Martin-Romano, Juan de Alvaro, Stefania Salvagni, Zariana Nikolova, Antoine Hollebecque, Giuseppe Curigliano, Jaume Capdevila, Sheila Mora, Marina Arias, Manisha Lamba, Josep L. Parra-Palau, Eric Baudin, Jorge Di Martino, Johann S. de Bono
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(2)
Purpose: Lysine-specific demethylase 1 (LSD1) is implicated in multiple tumor types, and its expression in cancer stem cells is associated with chemoresistance. CC-90011 is a potent, selective, and reversible oral LSD1 inhibitor. We examined CC-90011